Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer ; volume:7 ; number:1 ; day:29 ; month:3 ; year:2019 ; pages:1-14 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (29.3.2019), 1-14, 12.2019
- Urheber
-
Griguolo, Gaia
Pascual, Tomás
Dieci, Maria Vittoria
Guarneri, Valentina
Prat, Aleix
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0548-6
- URN
-
urn:nbn:de:101:1-2019042019412115910423
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Griguolo, Gaia
- Pascual, Tomás
- Dieci, Maria Vittoria
- Guarneri, Valentina
- Prat, Aleix
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases